GlucoTrack Inc GCTK 深 沪
等待开盘 08-10 09:30:00 美东时间
0.4322
-0.039
-8.34%
华盛通- 最 高0.783
- 今 开0.4659
- 成交量 93.70万股
- 最 低 0.3999
- 昨 收 0.4715
- 总市值 6682.58996
- 52周最高 14.1399
- 市盈率 静 --
- 换手率 6059.78%
- 52周最低 0.25
- 委 比 -19.43%
- 总股本 1.55万
- 历史最高 15.90
- 量 比 0.01
- 振 幅 81.25%
- 历史最低 0.00
- 每 手 1
- 风险率 2.55%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Glucotrack Completes Bridge Financing To Support Its Growth Plans
Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), together with its operating business Lōkahi Therapeutics™ ("Lōkahi"), a clinical-stage biopharmaceutical company advancing
07-17 20:07
GlucoTrack (GCTK) Stock Rallies 16% After Hours: Here's What Is Going On
GlucoTrack shares jumped 15.98% after-hours as investors reacted to Lokahi Therapeutics merger news and restructuring plans.
07-17 15:13
GlucoTrack Q4 EPS $(3.97) Up From $(1.24 thousand) YoY
GlucoTrack (NASDAQ:GCTK) reported quarterly losses of $(3.97) per share. This is a 99.68 percent increase over losses of $(1.24 thousand) per share from the same period last year.
03-31 05:08
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers ENvue Medical (NASDAQ:FEED) stock rose 80.4% to $4.15 during Thursday'...
01-30 01:05
Glucotrack Announces Reverse Stock Split Shareholder Approved Action Meets NASDAQ Panel Hearing Listing Requirements
Glucotrack, Inc. will implement a 1-for-60 reverse stock split on June 16, 2025, reducing outstanding shares from 32.5 million to ~542,356. The move aims to meet Nasdaq's $1.00 minimum bid price requirement and attract more institutional investors. Fractional shares will round up to whole shares, and no stockholder action is needed. Full details available on Glucotrack’s website.
2025-06-12 13:05
Glucotrack to Showcase Long-Term Continuous Blood Glucose Monitor at American Diabetes Association’s 85th Scientific Sessions
Glucotrack will present its implantable continuous blood glucose monitoring system's safety and performance data at the American Diabetes Association's 85th Scientific Sessions. The presentation highlights the technology's direct blood glucose measurement, eliminating the need for wearables and lasting up to three years.
2025-06-04 12:30
Glucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhD
Experienced medical device executive Victoria E. Carr-Brendel, PhD, joins Glucotrack's Board of Directors to advance the development of its long-term implantable blood glucose monitoring technology, offering a more accurate and convenient solution for people with diabetes.
2025-05-28 12:30
